Bionano Genomics, Inc. (BNGO) Q4 and Full Year 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Revenue: $8.0 million, down 3% from $8.2 million in Q4 2024, but within the preannounced range.

Full Year 2025 Revenue: $28.5 million, down 7% from $30.8 million in 2024. Core revenue, adjusted for clinical services, was down 2%.

Flow Cell Sales: 7,554 units sold in Q4, a 6% decline year-over-year; 30,171 units sold for the full year, down 0.4%.

Non-GAAP Gross Margin: Q4 margin at 43%, up from 42% a year ago; full year margin at 47%, a significant improvement from 35% in 2024.

Operating Expenses: Q4 non-GAAP operating expenses were $9.7 million, down 9% year-over-year; full year expenses were $36.6 million, down 47% from $68.9 million in 2024.

Cash Position: Ended 2025 with $29.6 million in cash and equivalents, with a runway extending into 2027.

2Strategic Updates and Business Highlights

Strategic Shift: Since September 2024, Bionano has focused on profitable growth from high-volume users rather than aggressive expansion of its installed base.

Key Strategic Pillars: 1. Support existing OGM users. 2. Increase utilization of optical genome mapping (OGM). 3. Build support for reimbursement and guidelines. 4. Improve profitability through cost management and product quality.

Publications and Reimbursement: 2025 saw a record 136 new peer-reviewed publications supporting OGM, and significant advancements in reimbursement with a new Category I CPT code for OGM, increasing the reimbursement rate for hematologic malignancies by 47%.

Customer Focus: Emphasis on routine-use customers, who represent a significant portion of consumables revenue.

3Forward Guidance and Outlook

2026 Revenue Guidance: $30 million to $33 million, indicating growth of 5% to 16% over 2025.

Q1 2026 Guidance: Expected revenue of $6.5 million to $6.7 million, flat to 3% growth year-over-year.

Growth Drivers: Anticipated growth from existing customers and new system installations, with a focus on routine-use customers.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Both Q4 and full-year revenues declined compared to the previous year, raising concerns about overall demand.

Flow Cell Sales: A slight decrease in flow cell sales, attributed to supply constraints due to manufacturing delays, which may impact future sales.

Customer Stability: The transition in strategy raised uncertainties regarding customer stability and demand during 2025.

5Notable Q&A Insights

New OGM Systems: Management refrained from providing specific guidance on the number of new OGM systems expected to be installed in 2026, suggesting a cautious approach.

Flow Cell Sales Expectations: Management indicated that consumable sales volume is expected to align with revenue growth, despite recent supply constraints.

Catalysts for Growth: The increase in reimbursement rates for OGM is seen as a major catalyst for future growth and adoption. Overall, Bionano Genomics is navigating a transitional phase with a strategic focus on profitability and customer utilization, while facing challenges in revenue growth and supply chain constraints. The outlook for 2026 appears cautiously optimistic, driven by improved reimbursement structures and a targeted customer approach.